

CITATION REPORT

List of articles citing

ALK-rearrangement in non-small-cell lung cancer (NSCLC)

DOI: 10.1111/1759-7714.12613
Thoracic Cancer, 2018, 9, 423-430.

Source: <https://exaly.com/paper-pdf/68826376/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
131	An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer. 2019 , 20, 1551-1561		1
130	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. 2019 , 6, 233		8
129	Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment. 2019 , 14, e0222233		4
128	Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer. 2019 , 15, 2163-2174		0
127	Lung cancer breath tests. 2019 , 13, 597-599		4
126	First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future development. 2019 , 1-7		1
125	RNA 2FO-Methylation (Nm) Modification in Human Diseases. 2019 , 10,		66
124	Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020 , 11, 103-112	3.2	11
123	Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. 2020 , 146, 935-944		10
122	Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. 2020 , 15, 383-391		30
121	A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy. 2020 , 19, 370-384		2
120	Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. 2020 , 149, 154-161		8
119	[Fusion transcripts: Therapeutic targets in thoracic oncology]. 2020 , 107, 896-903		1
118	Tyrosine Kinase Receptors in Oncology. 2020 , 21,		12
117	Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions. 2020 , 1-19		6
116	Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study. 2020 , 147, 130-136		5
115	Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer. 2020 , 7, 261-269		3

114	Coexisting of and Acquired in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report. 2020 , 13, 8313-8316		2
113	Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. 2020 , 10, 725		1
112	Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non-Small-Cell Lung Cancer. 2020 , 22, 1438-1452		2
111	Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study. 2020 , 20, 479		2
110	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients. 2020 , 146, 209-216		1
109	Pharmacological and clinical properties of lorlatinib in the treatment of -rearranged advanced non-small cell lung cancer. 2020 , 21, 1547-1554		4
108	N-[F]-Fluoroacetylcrizotinib: A potentially potent and selective PET tracer for molecular imaging of non-small cell lung cancer. 2020 , 30, 127257		0
107	Clinical evaluation of the effectiveness of fusion-induced asymmetric transcription assay-based reverse transcription droplet digital PCR for ALK detection in formalin-fixed paraffin-embedded samples from lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 2252-2261	3.2	4
106	Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report. <i>Thoracic Cancer</i> , 2020 , 11, 1695-1698	3.2	3
105	A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib. 2020 , 142, 59-62		6
104	StALKing Histiocytosis: ALK-Positive Histiocytosis Identified through Peripheral Blood Smear. 2021 , 144, 241-243		0
103	Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor. 2021 , 48, 425-428		1
102	Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice. 2021 , 10,		13
101	Analysis of Clinical Features of ALK Rearrangement Lung Cancer. 2021 , 11, 1-8		
100	Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients. 2021 , 152, 104-108		1
99	Network pharmacology-based study to explore the mechanism of the Yiqi Gubiao pill in lung cancer treatment. 2021 , 21, 321		0
98	Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. 2021 , 14, 62		14
97	Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics. 2021 , 23, 31		6

96	Identification of Novel Alectinib-Resistant Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling. 2021 , 14, 2131-2138	3
95	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. 2021 , 94, 102169	4
94	Concomitant mutation status of -rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. 2021 , 10, 1525-1535	3
93	Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer. 2021 , 11, 655856	1
92	A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma. 2021 , 11, 603882	9
91	A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib. 2021 , 22, e799-e803	0
90	A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation. 2021 , 53, 601-606	2
89	Identification of combinations of somatic mutations that predict cancer survival and immunotherapy benefit. 2021 , 3, zcab017	1
88	Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach. 2021 , 22,	5
87	Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall. 2021 , 45, 1707-1719	5
86	An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance. 2021 ,	1
85	The importance of precision medicine in modern molecular oncology. 2021 , 100, 248-257	2
84	An ocular lesion of unknown aetiology. 2021 , 17, 200164	
83	Effects of MicroRNA-22 (miR-222) on Non-Small-Cell Lung Carcinoma (NSCLC) Cells Apoptosis and Proliferation Through Protein Kinase B/Mammalian Target of Rapamycin (AKT/mTOR) Signaling Pathway. 2021 , 11, 1346-1351	
82	Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATIONAL study group. 2021 , 1, 123-123	0
81	Hypoxia in Lung Cancer Management: A Translational Approach. <i>Cancers</i> , 2021 , 13,	6.6 2
80	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. 2021 , 16, 2040-2050	4
79	Molecular Docking, 3D-QSAR, Fingerprint-Based 2D-QSAR, Analysis of Pyrimidine, and Analogs of ALK (Anaplastic Lymphoma Kinase) Inhibitors as an Anticancer Agent. 2021 , 18, 509-521	0

78	Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. 2021,	2
77	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. 2021, 158, 126-136	9
76	Methods for actionable gene fusion detection in lung cancer: now and in the future. 2021, 22, 833-847	0
75	ALK-positive pulmonary adenocarcinoma with signet ring features (PASRF) and polygonal cell morphology simultaneously co-expressing TTF-1/p63/P40: a case report.. 2021, 10, 3864-3869	0
74	Biomarkers in oncology. 2021, 195-202	
73	Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. 2021, 11,	8
72	The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology. 2020, 10, 570465	13
71	The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma. 2020, 2020, 3578748	3
70	A mark of disease: how mRNA modifications shape genetic and acquired pathologies. 2021, 27, 367-389	6
69	Epithelial-Mesenchymal Transition: Role in Cancer Progression and the Perspectives of Antitumor Treatment. 2020, 12, 4-23	4
68	Targeted Therapy for Non-Small Cell Lung Cancer. 2020, 95, 78-88	1
67	The genomic landscape of lung adenocarcinoma insights towards personalized medicine. 2021, 87, 562	
66	Treatment of patients with non-small cell lung cancer with ALK rearrangement. 2018, 12, 182-184	
65	[Epidemiology and diagnosis of mutations in the ALK gene in patients with non-small cell lung cancer in the Moscow region]. 2020, 82, 18-23	
64	Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. 2021, 11,	4
63	Targeting lung cancer using advanced drug delivery systems. 2020, 493-516	1
62	New-Generation Anaplastic Lymphoma Kinase Inhibitor Experience in a Case With Non-Small Cell Lung Cancer: High Efficacy but Unexpected Toxicity. 2020, 28, e799-e801	
61	Exome sequencing identified six copy number variations as a prediction model for recurrence of primary prostate cancers with distinctive prognosis.. 2020, 9, 2231-2242	0

60	Fibroblast growth factor receptor fusions in cancer: opportunities and challenges. 2021 , 40, 345		7
59	Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer in the Middle East and North Africa. 2021 , 7, 1556-1563		1
58	Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription.. 2021 ,		0
57	Effect of Chemotherapy on Immune Factors in Patients with Non-Small Cell Lung Cancer. 2021 , 09, 110-117		
56	Global research Trends in Tyrosine Kinase Inhibitors: A Co-Word and Visualized Study (Preprint).		
55	Global research Trends in Tyrosine Kinase Inhibitors: A Co-Word and Visualized Study.. 2022 ,		
54	The Extent of Expression of Thyroid Transcription Factor 1, Cytokeratin 7, and Anaplastic Lymphoma Kinase in Lung Adenocarcinoma.. 2022 , 10, 10-14		
53	Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	0
52	Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.. 2022 , 17, 27		0
51	Temporal trends in lung cancer survival: a population-based study. 2021 , 1-7		1
50	Case Report: A Pregnant Woman Diagnosed as ALK-Rearrangement Lung Large Cell Neuroendocrine Cancer With Brain Metastasis.. 2022 , 12, 823813		0
49	Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.. 2022 , 14, 843-850		0
48	Case Report: Patient With Lung Adenocarcinoma With Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment.. 2022 , 12, 762338		
47	Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update.. 2022 , 12, 859152		0
46	Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study.. 2022 , 13, 858279		2
45	The role of next-generation sequencing in detecting gene fusions with known and unknown partners: a single-center experience with methodologies integration.. 2022 , 123, 20-30		1
44	Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel Fusion Lung Adenocarcinoma: A Case Report.. 2021 , 14, 5471-5475		0
43	Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.. <i>Cancers</i> , 2021 , 13,	6.6	2

42 Role of in -positive non-small cell lung cancer.. **2022**, 23, 181

41 RadGenNets: Deep Learning-Based Radiogenomics Model For Gene Mutation Prediction In Lung Cancer. 0

40 Gold Nanoparticles Based Optical Biosensors for Cancer Biomarker Proteins: A Review of the Current Practices.. **2022**, 10, 877193 1

39 Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.. **2022**, 10, 0

38 A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer. **2022**, 12, 1297

37 Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression. 1

36 Non-Small Cell Lung Cancer: Treatment, Diagnosis, and Life after Treatment. **2022**, 13, 450-463

35 Targeting ALK in Neuroendocrine Tumors of the Lung. 12, 0

34 A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report. 12, 0

33 Establishing an 8-gene immune prognostic model based on TP53 status for lung adenocarcinoma. **2022**, 36, 0

32 A pharmacological exploration of targeted drug therapy in non-small cell lung cancer. **2022**, 39, 1

31 Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review. *Journal of Pathology and Translational Medicine*, **2022**, 56, 231-237 2.9 0

30 Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. *Cancers*, **2022**, 14, 3452 6.6 1

29 MET: A narrative review of exon 14 skipping mutation in non-small-cell lung carcinoma. **2022**, 5, 284

28 Searching for Novel Anaplastic Lymphoma Kinase Inhibitors: Structure-Guided Screening of Natural Compounds for a Tyrosine Kinase Therapeutic Target in Cancers. **2022**, 26, 461-470 1

27 Sotorasib and other drugs comparison in treating non-small cell lung cancer. 8, 675-686

26 Current treatments for non-small cell lung cancer. 12, 0

25 A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. **2022**, 243, 114742 0

- 24 A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report. **2022**, 17, 846-850 ○
- 23 RadGenNets: Deep learning-based radiogenomics model for gene mutation prediction in lung cancer. **2022**, 33, 101062 ○
- 22 Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer. **2022**, 11, 2871 1
- 21 The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives. **2022**, 14, 4765 1
- 20 Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose. 9, 1
- 19 Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer. **2022**, 29, 7816-7831 ○
- 18 Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review. 12, ○
- 17 The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC. **2022**, 43, 1217-1224 ○
- 16 Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report. 12, ○
- 15 Non-small-cell lung cancer-associated gene mutations and inhibitors. **2022**, 6, 100076 ○
- 14 Prognostic value of Beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer. **2022**, 13, ○
- 13 Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. **2022**, 20, ○
- 12 Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer. ○
- 11 Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. **2022**, 23, 15056 1
- 10 The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer. **2023**, 24, 1506 ○
- 9 Whole-exome sequencing revealed the mutational profiles of primary central nervous system lymphoma. **2023**, ○
- 8 Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma: A Case Series. **2023**, 30, 518-528 ○
- 7 Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia. ○

- 6 Piperidine Derivatives: Recent Advances in Synthesis and Pharmacological Applications. **2023**, 24, 2937 ○
- 5 A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma. **2023**, 23, ○
- 4 Liquid Biopsies in Lung Cancer. **2023**, 15, 1430 ○
- 3 Association of lung cancer with ALK and EGFR and its targeted therapy. 36, 560-566 ○
- 2 Mutation Status Analysis Of 58 Patients With Advanced ALK Fusion Gene Positive Non Small Cell Lung Cancer. ○
- 1 Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review. 13, ○